Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer
ConclusionsWe identified a stemness-related gene panel associated with JQ1 and describe how this inhibitor modifies the stemness landscape in TNBC. Therefore, we propose a novel role for JQ1 as a stemness-targeting drug. Loss of the stem cell phenotype via JQ1 treatment could lead to less aggressive and more chemo-sensitive tumours, reflecting a better patient prognosis. Thus, the identified gene panel may be of interest for the clinical management of patients with aggressive TNBC.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Databases & Libraries | Epithelial Cancer | Genetics | Stem Cell Therapy | Stem Cells | Study